# Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di

Source: https://onco.cc/trials/nct07071961/  
OnCo record `nct07071961` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of regorafenib and lorigerlimab in colorectal cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial] is a phase 2, interventional study registered as NCT07071961 by M.D. Anderson Cancer Center, with a registry enrolment figure of 16 participants, started 2026-02-11 and due to reach its primary completion in 2027-05-01. Interventions recorded: Regorafenib (CT); Lorigerlimab. Conditions listed: Colorectal Cancer; Regorafenib; High Risk Patients. Primary outcome: Safety and adverse events (AEs). Colorectal eligibility wording from the registry: "* History of hysterectomy or bilateral salpingo-oophorectomy". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07071961
- Phase: 2
- Setting: Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Disease After End of Established Definitive Therapy [ReLOAD Trial]
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 16

## Sources

- ClinicalTrials.gov NCT07071961: https://clinicaltrials.gov/study/NCT07071961

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [MRD / molecular residual disease testing](https://onco.cc/technologies/mrd-testing/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Lorigerlimab](https://onco.cc/drugs/lorigerlimab/), [Regorafenib](https://onco.cc/drugs/regorafenib/)
- companies: [Bayer](https://onco.cc/companies/bayer/), [MacroGenics](https://onco.cc/companies/macrogenics/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07071961.json